ClinicalTrials.gg
CompletedNCT00171054Updated Jun 6, 2011Results posted

Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension

A Phase 4 interventional study of Valsartan 320 mg and Amlodipine 10 mg in Hypertension, sponsored by Novartis. Completed at 1 site in Switzerland. Open to female participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-06-06.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
84th of 139
125 · median 198
Started
2003
with 12 others
Phase 4
67 of 140
none open now
Registered
7th of 140
by date
Lead sponsor
69 of 140
Novartis

Among the 140 studies testing valsartan in Hypertension, this one is the 84th largest by enrollment of the 139 interventional ones that give a count, is one of 13 that started in 2003, is one of 67 in phase 4, and was the 7th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 50 Years to 75 Years · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

The purpose of this study is compare treatment with valsartan with the possible addition of a diuretic, hydrochlorothiazide, on high blood pressure with the drug amlodipine with the possible addition of a diuretic, hydrochlorothiazide. In particular, the effect of treatment on the stiffness of the blood vessels will be studied.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • hypertension
  • postmenopausal
  • valsartan
  • amlodipine
  • hydrochlorothiazide
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
Female

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women
  • Mild to moderate hypertension
  • Statin therapy or LDL≤ 4.1 mmol/L

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension
  • LDL > 4.1 mmol/L if not taking anti-hyperlipidemic medication
  • Certain hormonal therapy
  • History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm
  • Liver, kidney, or pancreas disease
  • Diabetes
  • Raynaud's disease or any other significant peripheral vascular disease
  • Allergy to certain medications used to treat high blood pressure

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Valsartan 320 mg

    Drug: Valsartan 320 mg · Drug: Hydrochlorothiazide

  • Experimental
    Amlodipine 10 mg

    Drug: Amlodipine 10 mg · Drug: Hydrochlorothiazide

Interventions

  • DrugValsartanStudies of ValsartanValsartan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients received 160 mg valsartan for 4 weeks. Patients were then up-titrated to receive either 320 mg valsartan for the following 8 weeks.

  • DrugAmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients received 5 mg amlodipine for four weeks. Patients were then up-titrated to receive 10 mg amlodipine for the following 8 weeks.

  • At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure \< 140 mmHg and Diastolic Blood Pressure \< 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 38 in the Carotid-femoral Pulse Wave Velocity (PWV)

    PWV was determined from transcutaneous Doppler flow recordings and the foot-to-foot method triggered by the simultaneous ECG. Two simultaneous Doppler flow tracings were taken at the left common carotid and the right femoral artery in the groin with a linear array probe. The time delay (t) was measured between R wave of the ECG and the base of the flow waves recorded at these points, and averaged over 10 beats. The distance (D) traveled by the pulse wave was measured over body surface as the distance from the suprasternal notch to the carotid artery. PWV was calculated as PWV=D/t.

    Time frame: Baseline and Week 38

Secondary outcomes

  1. Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Week 12

    Cutaneous blood flow was continuously recorded by a laser Doppler flowmeter. The laser Doppler flow probe was applied on the volar part of the right forearm with a plastic holder 10 cm proximal to the wrist. All measurements were made with a pressure cuff on the arm and inflated 20 mmHg above systolic BP and maintained for 2 min then rapidly deflated. All measurements were made in a quiet room with a patient in the supine position. The maximal reactive hyperemia was measured after cuff deflation, which allows measurement of the right forearm postischemic skin reactive hyperemia (SRH).

    Time frame: Baseline and Week 12

  2. Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Endpoint (Week 38)

    Cutaneous blood flow was continuously recorded by a laser Doppler flowmeter. The laser Doppler flow probe was applied on the volar part of the right forearm with a plastic holder 10 cm proximal to the wrist. All measurements were made with a pressure cuff on the arm and inflated 20 mmHg above systolic BP and maintained for 2 min then rapidly deflated. All measurements were made in a quiet room with a patient in the supine position. The maximal reactive hyperemia was measured after cuff deflation, which allows measurement of the right forearm postischemic skin reactive hyperemia (SRH).

    Time frame: Week 38

  3. Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at Week 12

    Endothelial function will be assessed using high-resolution duplex ultrasound with wall tracking to measure FMD of the brachial artery during reactive hyperemia. FMD of the brachial artery in response to reactive hyperemia in the distal forearm (and glyceryl trinitrate as a non-endothelium dependent control) will be measured from B-mode ultrasound images using a standard 7 MHz linear array transducer and HDI 5000 system with edge detection.

    Time frame: Baseline and Week 12

  4. Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at End-point (Week 38)

    Endothelial function will be assessed using high-resolution duplex ultrasound with wall tracking to measure FMD of the brachial artery during reactive hyperemia. FMD of the brachial artery in response to reactive hyperemia in the distal forearm (and glyceryl trinitrate as a non-endothelium dependent control) will be measured from B-mode ultrasound images using a standard 7 MHz linear array transducer and HDI 5000 system with edge detection.

    Time frame: Baseline and Week 38

  5. Changes in Mean Left Carotid Distensibility at Week 12

    For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe. Absolute diameter and diameter changes over the cardiac cycles will be recorded. Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.

    Time frame: Baseline and Week 12

  6. Changes in Mean Left Carotid Distensibility at Week 38

    For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe. Absolute diameter and diameter changes over the cardiac cycles will be recorded. Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.

    Time frame: Baseline and Week 38

  7. Changes in Mean Right Carotid Distensibility at Week 12

    For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe. Absolute diameter and diameter changes over the cardiac cycles will be recorded. Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.

    Time frame: Baseline and Week 12

  8. Changes in Mean Right Carotid Distensibility at Week 38

    For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe. Absolute diameter and diameter changes over the cardiac cycles will be recorded. Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.

    Time frame: Baseline and Week 38

  9. Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 12

    The calculation of spontaneous baroflex sensitivity was obtained by the sequence method. Baroflex sequences are defined by at least three consecutive beats in which the systolic blood pressure and the RR interval of the following beat either both increased or decreased. The slope of each individual sequence is computed and the mean slope is determined as the average of all slopes within a given period of time and taken as the gain of the cardiac baroflex (BRSs).

    Time frame: Baseline and Week 12

  10. Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 38

    The calculation of spontaneous baroflex sensitivity was obtained by the sequence method. Baroflex sequences are defined by at least three consecutive beats in which the systolic blood pressure and the RR interval of the following beat either both increased or decreased. The slope of each individual sequence is computed and the mean slope is determined as the average of all slopes within a given period of time and taken as the gain of the cardiac baroflex (BRSs).

    Time frame: Baseline and Week 38

  11. Change in Left Ventricular Mass Index (LVMI) and Diastolic Function Using Echocardiography From Baseline to Week 38

    Time frame: Baseline and Week 38

  12. Changes in Central Blood Pressure, Evaluated by Applanation Tonometry From Baseline at Weeks 12 and 38

    Central Blood Pressure was measured via applanation tonometry recordings of the common carotid artery and from brachial oscillometric recordings. The Simultaneously obtained carotid artery pressure and standard brachial artery blood pressure are computed to obtain the central systolic pressure.

    Time frame: Baseline, Week 12 and Week 38

07

Results

Posted May 3, 2011

Participant flow

Participant flow — Overall Study
MilestoneValsartan 320 mgAmlodipine 10 mg
Started6362
Completed5350
Not completed1012
Withdrew: Protocol violation12
Withdrew: Patient withdrew consent10
Withdrew: Lost to follow-up01
Withdrew: Adverse event88
Withdrew: Condition no longer required study drug01

Outcome measures

PrimaryChange From Baseline to Week 38 in the Carotid-femoral Pulse Wave Velocity (PWV)

PWV was determined from transcutaneous Doppler flow recordings and the foot-to-foot method triggered by the simultaneous ECG. Two simultaneous Doppler flow tracings were taken at the left common carotid and the right femoral artery in the groin with a linear array probe. The time delay (t) was measured between R wave of the ECG and the base of the flow waves recorded at these points, and averaged over 10 beats. The distance (D) traveled by the pulse wave was measured over body surface as the distance from the suprasternal notch to the carotid artery. PWV was calculated as PWV=D/t.

Time frame:
Baseline and Week 38
Reported as:
Least squares mean · m/s
Change From Baseline to Week 38 in the Carotid-femoral Pulse Wave Velocity (PWV)
m/sValsartan 320 mgAmlodipine 10 mg
Change From Baseline to Week 38 in the Carotid-femoral Pulse Wave Velocity (PWV)-1.9 ± 0.29-1.7 ± 0.30
SecondaryChange From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Week 12

Cutaneous blood flow was continuously recorded by a laser Doppler flowmeter. The laser Doppler flow probe was applied on the volar part of the right forearm with a plastic holder 10 cm proximal to the wrist. All measurements were made with a pressure cuff on the arm and inflated 20 mmHg above systolic BP and maintained for 2 min then rapidly deflated. All measurements were made in a quiet room with a patient in the supine position. The maximal reactive hyperemia was measured after cuff deflation, which allows measurement of the right forearm postischemic skin reactive hyperemia (SRH).

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Perfusion units
Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Week 12
Perfusion unitsValsartan 320 mgAmlodipine 10 mg
Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Week 1225.4 ± 14.88-105.6 ± 15.31
SecondaryChange From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Endpoint (Week 38)

Cutaneous blood flow was continuously recorded by a laser Doppler flowmeter. The laser Doppler flow probe was applied on the volar part of the right forearm with a plastic holder 10 cm proximal to the wrist. All measurements were made with a pressure cuff on the arm and inflated 20 mmHg above systolic BP and maintained for 2 min then rapidly deflated. All measurements were made in a quiet room with a patient in the supine position. The maximal reactive hyperemia was measured after cuff deflation, which allows measurement of the right forearm postischemic skin reactive hyperemia (SRH).

Time frame:
Week 38
Reported as:
Least squares mean · Perfusion units
Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Endpoint (Week 38)
Perfusion unitsValsartan 320 mgAmlodipine 10 mg
Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Endpoint (Week 38)-9.7 ± 13.73-94.6 ± 14.20
SecondaryChange From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at Week 12

Endothelial function will be assessed using high-resolution duplex ultrasound with wall tracking to measure FMD of the brachial artery during reactive hyperemia. FMD of the brachial artery in response to reactive hyperemia in the distal forearm (and glyceryl trinitrate as a non-endothelium dependent control) will be measured from B-mode ultrasound images using a standard 7 MHz linear array transducer and HDI 5000 system with edge detection.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent
Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at Week 12
percentValsartan 320 mgAmlodipine 10 mg
Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at Week 12-8.7 ± 0.35-8.6 ± 0.38
SecondaryChange From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at End-point (Week 38)

Endothelial function will be assessed using high-resolution duplex ultrasound with wall tracking to measure FMD of the brachial artery during reactive hyperemia. FMD of the brachial artery in response to reactive hyperemia in the distal forearm (and glyceryl trinitrate as a non-endothelium dependent control) will be measured from B-mode ultrasound images using a standard 7 MHz linear array transducer and HDI 5000 system with edge detection.

Time frame:
Baseline and Week 38
Reported as:
Least squares mean · percent
Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at End-point (Week 38)
percentValsartan 320 mgAmlodipine 10 mg
Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at End-point (Week 38)-8.1 ± 0.53-8.2 ± 0.56
SecondaryChanges in Mean Left Carotid Distensibility at Week 12

For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe. Absolute diameter and diameter changes over the cardiac cycles will be recorded. Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent
Changes in Mean Left Carotid Distensibility at Week 12
percentValsartan 320 mgAmlodipine 10 mg
Changes in Mean Left Carotid Distensibility at Week 120.0 ± 0.140.0 ± 0.15
SecondaryChanges in Mean Left Carotid Distensibility at Week 38

For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe. Absolute diameter and diameter changes over the cardiac cycles will be recorded. Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.

Time frame:
Baseline and Week 38
Reported as:
Least squares mean · percent
Changes in Mean Left Carotid Distensibility at Week 38
percentValsartan 320 mgAmlodipine 10 mg
Changes in Mean Left Carotid Distensibility at Week 380.0 ± 0.160.1 ± 0.16
SecondaryChanges in Mean Right Carotid Distensibility at Week 12

For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe. Absolute diameter and diameter changes over the cardiac cycles will be recorded. Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent
Changes in Mean Right Carotid Distensibility at Week 12
percentValsartan 320 mgAmlodipine 10 mg
Changes in Mean Right Carotid Distensibility at Week 12-0.4 ± 0.160.1 ± 0.17
SecondaryChanges in Mean Right Carotid Distensibility at Week 38

For carotid distensibility, the left and right bulbs and common carotid arteries are measured using tissue Doppler imaging with the linear array probe. Absolute diameter and diameter changes over the cardiac cycles will be recorded. Distensibility of each bulb will be calculated for three consecutive heart cycles and averaged and corrected for blood pressure.

Time frame:
Baseline and Week 38
Reported as:
Least squares mean · percent
Changes in Mean Right Carotid Distensibility at Week 38
percentValsartan 320 mgAmlodipine 10 mg
Changes in Mean Right Carotid Distensibility at Week 38-0.2 ± 0.170.0 ± 0.17
SecondaryChanges in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 12

The calculation of spontaneous baroflex sensitivity was obtained by the sequence method. Baroflex sequences are defined by at least three consecutive beats in which the systolic blood pressure and the RR interval of the following beat either both increased or decreased. The slope of each individual sequence is computed and the mean slope is determined as the average of all slopes within a given period of time and taken as the gain of the cardiac baroflex (BRSs).

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · EP
Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 12
EPValsartan 320 mgAmlodipine 10 mg
Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 121.5 ± 1.71-1.5 ± 1.78
SecondaryChanges in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 38

The calculation of spontaneous baroflex sensitivity was obtained by the sequence method. Baroflex sequences are defined by at least three consecutive beats in which the systolic blood pressure and the RR interval of the following beat either both increased or decreased. The slope of each individual sequence is computed and the mean slope is determined as the average of all slopes within a given period of time and taken as the gain of the cardiac baroflex (BRSs).

Time frame:
Baseline and Week 38
Reported as:
Least squares mean · EP
Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 38
EPValsartan 320 mgAmlodipine 10 mg
Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 38-2.0 ± 1.380.1 ± 1.44
SecondaryChange in Left Ventricular Mass Index (LVMI) and Diastolic Function Using Echocardiography From Baseline to Week 38
Time frame:
Baseline and Week 38
Reported as:
Least squares mean · percent
Change in Left Ventricular Mass Index (LVMI) and Diastolic Function Using Echocardiography From Baseline to Week 38
percentValsartan 320 mgAmlodipine 10 mg
Change in Left Ventricular Mass Index (LVMI) and Diastolic Function Using Echocardiography From Baseline to Week 38-4.8 ± 2.43-6.2 ± 2.13
SecondaryChanges in Central Blood Pressure, Evaluated by Applanation Tonometry From Baseline at Weeks 12 and 38

Central Blood Pressure was measured via applanation tonometry recordings of the common carotid artery and from brachial oscillometric recordings. The Simultaneously obtained carotid artery pressure and standard brachial artery blood pressure are computed to obtain the central systolic pressure.

Time frame:
Baseline, Week 12 and Week 38
Reported as:
Least squares mean · mm Hg
Changes in Central Blood Pressure, Evaluated by Applanation Tonometry From Baseline at Weeks 12 and 38
mm HgValsartan 320 mgAmlodipine 10 mg
Week 12-9.1 ± 1.06-14.2 ± 1.10
Week 36-11.1 ± 1.07-13.9 ± 1.12

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valsartan 320 mg—2/63 (3.2%)35/63 (55.6%)
Amlodipine 10 mg—2/62 (3.2%)51/62 (82.3%)
Most frequent serious events
Most frequent serious events
EventValsartan 320 mgAmlodipine 10 mg
DiplopiaEye disorders0/631/62
Cerebrovascular accidentNervous system disorders0/631/62
Laryngeal oedemaRespiratory, thoracic and mediastinal disorders0/631/62
SyncopeNervous system disorders1/630/62
Transient ischaemic attackNervous system disorders1/630/62
Most frequent other events
Most frequent other events
EventValsartan 320 mgAmlodipine 10 mg
Oedema peripheralGeneral disorders9/6348/62
BronchitisInfections and infestations8/630/62
HeadacheNervous system disorders6/635/62
AstheniaGeneral disorders5/632/62
HypotensionVascular disorders5/630/62
FatigueGeneral disorders0/634/62
Muscle spasmsMusculoskeletal and connective tissue disorders2/634/62
Pain in extremityMusculoskeletal and connective tissue disorders1/634/62
VertigoEar and labyrinth disorders4/632/62
InsomniaPsychiatric disorders4/631/62

Baseline characteristics

Age Continuous
Age Continuous(years)Valsartan 320 mgAmlodipine 10 mgTotal
Mean62.3 ± 5.7660.4 ± 5.0861.4 ± 5.50
Sex: Female, Male
Sex: Female, Male(Participants)Valsartan 320 mgAmlodipine 10 mgTotal
Female6362125
Male000
08

Study locations

1 site
  • Novartis Pharmaceuticals
    Basel, Switzerland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2003, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2005
First posted
Sep 15, 2005
Start
Sep 2003
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Results first posted
May 3, 2011
Last update
Jun 6, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00171054
Lead sponsor
Novartis
First posted
Sep 15, 2005
Start date
Sep 2003
Primary completion
Oct 2007
Completion
Oct 2007
Results posted
May 3, 2011
Last update
Jun 6, 2011

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valsartan · Amlodipine

Start the discussion